RecruitingPhase 1NCT07083960
OM336 in Autoimmune Cytopenias
An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants With Active Autoimmune Cytopenias
Sponsor
Ouro Medicines
Enrollment
32 participants
Start Date
Aug 1, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria4
- Active autoimmune cytopenia
- Relapsed/refractory after ≥1 prior treatment
- Body weight ≥ 55 kg
- Willing to comply with and study requirements and procedures
Exclusion Criteria4
- Previous treatment with a BCMA-targeted therapy
- Clinically significant infection within 3 months of screening
- Major surgery or splenectomy within 3 months of screening or planned during the study
- Pregnant or breastfeeding
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGOM336
OM336 is an engineered bispecific antibody directed against BCMA and CD3
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07083960
Related Trials
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
NCT071948508 locations
Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study
NCT071336591 location
Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura
NCT070936061 location
National Longitudinal Cohort of Hematological Diseases- Autoimmune Hemolytic Anemia
NCT070190381 location
RESTI Registry: Spanish Registry of Primary Immune Thrombocytopenia and Other Immune Thrombocytopenia
NCT0691934136 locations